Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder

Yechiel Levkovitz, Jonathan E. Alpert, Carrie E. Brintz, David Mischoulon, George I. Papakostas

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosyl methionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Methods: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (p = 0.04) and a trend toward statistical significance for greater improvement in word-finding (p = 0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusion: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.

Original languageEnglish (US)
Pages (from-to)1174-1178
Number of pages5
JournalJournal of Affective Disorders
Volume136
Issue number3
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

S-Adenosylmethionine
Neurobehavioral Manifestations
Major Depressive Disorder
Serotonin Uptake Inhibitors
Methionine
Antidepressive Agents
Aptitude
Neurotransmitter Agents
Placebos
Maintenance
Tissue Donors
Clinical Trials
Therapeutics

Keywords

  • Cognitive function
  • Major depression
  • One-carbon cycle
  • S-adenosylmethionine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. / Levkovitz, Yechiel; Alpert, Jonathan E.; Brintz, Carrie E.; Mischoulon, David; Papakostas, George I.

In: Journal of Affective Disorders, Vol. 136, No. 3, 02.2012, p. 1174-1178.

Research output: Contribution to journalArticle

Levkovitz, Yechiel ; Alpert, Jonathan E. ; Brintz, Carrie E. ; Mischoulon, David ; Papakostas, George I. / Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. In: Journal of Affective Disorders. 2012 ; Vol. 136, No. 3. pp. 1174-1178.
@article{34b2f8d336c544e2b0a06b121a4c22a1,
title = "Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder",
abstract = "Background: Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosyl methionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Methods: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (p = 0.04) and a trend toward statistical significance for greater improvement in word-finding (p = 0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusion: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.",
keywords = "Cognitive function, Major depression, One-carbon cycle, S-adenosylmethionine",
author = "Yechiel Levkovitz and Alpert, {Jonathan E.} and Brintz, {Carrie E.} and David Mischoulon and Papakostas, {George I.}",
year = "2012",
month = "2",
doi = "10.1016/j.jad.2011.04.059",
language = "English (US)",
volume = "136",
pages = "1174--1178",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder

AU - Levkovitz, Yechiel

AU - Alpert, Jonathan E.

AU - Brintz, Carrie E.

AU - Mischoulon, David

AU - Papakostas, George I.

PY - 2012/2

Y1 - 2012/2

N2 - Background: Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosyl methionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Methods: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (p = 0.04) and a trend toward statistical significance for greater improvement in word-finding (p = 0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusion: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.

AB - Background: Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosyl methionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Methods: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (p = 0.04) and a trend toward statistical significance for greater improvement in word-finding (p = 0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusion: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.

KW - Cognitive function

KW - Major depression

KW - One-carbon cycle

KW - S-adenosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=84857368903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857368903&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2011.04.059

DO - 10.1016/j.jad.2011.04.059

M3 - Article

C2 - 21911258

AN - SCOPUS:84857368903

VL - 136

SP - 1174

EP - 1178

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 3

ER -